PL3348264T3 - Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)- 2-metylofenylo]metanolu do obniżania ciśnienia śródgałkowego - Google Patents
Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)- 2-metylofenylo]metanolu do obniżania ciśnienia śródgałkowegoInfo
- Publication number
- PL3348264T3 PL3348264T3 PL18160174T PL18160174T PL3348264T3 PL 3348264 T3 PL3348264 T3 PL 3348264T3 PL 18160174 T PL18160174 T PL 18160174T PL 18160174 T PL18160174 T PL 18160174T PL 3348264 T3 PL3348264 T3 PL 3348264T3
- Authority
- PL
- Poland
- Prior art keywords
- imidazol
- methylphenyl
- drugs
- methanol
- ethyl
- Prior art date
Links
- HTQCEFAVROSRIW-UHFFFAOYSA-N [3-[1-(1h-imidazol-5-yl)ethyl]-2-methylphenyl]methanol Chemical compound C=1C=CC(CO)=C(C)C=1C(C)C1=CNC=N1 HTQCEFAVROSRIW-UHFFFAOYSA-N 0.000 title 1
- 150000002148 esters Chemical class 0.000 title 1
- 230000004410 intraocular pressure Effects 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38337010P | 2010-09-16 | 2010-09-16 | |
| PCT/US2011/051990 WO2012037490A1 (en) | 2010-09-16 | 2011-09-16 | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
| EP16161922.6A EP3053576B1 (en) | 2010-09-16 | 2011-09-16 | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
| EP11760962.8A EP2616068B1 (en) | 2010-09-16 | 2011-09-16 | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for lowering intraocular pressure |
| EP18160174.1A EP3348264B1 (en) | 2010-09-16 | 2011-09-16 | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3348264T3 true PL3348264T3 (pl) | 2020-08-24 |
Family
ID=44675870
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16161920T PL3050563T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1 h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do leczenia chorób skóry i stanów skórnych |
| PL16161923T PL3050564T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu |
| PL16161922T PL3053576T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do obniżania ciśnienia śródgałkowego |
| PL18160174T PL3348264T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)- 2-metylofenylo]metanolu do obniżania ciśnienia śródgałkowego |
| PL18157147T PL3338777T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu do leczenia chorób siatkówki |
| PL11760963T PL2616069T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazolo-4-ilo)etylo)-2-metylofenylo]metanolu |
| PL11760962.8T PL2616068T3 (pl) | 2010-09-16 | 2011-09-16 | Proleki estrów pochodzących z [3-(1-(1h-imidazol-4-ilo)etylo)-2- metylofenylo]metanolu do obniżania ciśnienia śródgałkowego |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16161920T PL3050563T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1 h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do leczenia chorób skóry i stanów skórnych |
| PL16161923T PL3050564T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu |
| PL16161922T PL3053576T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo] metanolu do obniżania ciśnienia śródgałkowego |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18157147T PL3338777T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazol-4-ilo)etylo)-2-metylofenylo]metanolu do leczenia chorób siatkówki |
| PL11760963T PL2616069T3 (pl) | 2010-09-16 | 2011-09-16 | Estrowe proleki [3-(1-(1h-imidazolo-4-ilo)etylo)-2-metylofenylo]metanolu |
| PL11760962.8T PL2616068T3 (pl) | 2010-09-16 | 2011-09-16 | Proleki estrów pochodzących z [3-(1-(1h-imidazol-4-ilo)etylo)-2- metylofenylo]metanolu do obniżania ciśnienia śródgałkowego |
Country Status (28)
| Country | Link |
|---|---|
| US (9) | US8653123B2 (pl) |
| EP (13) | EP3338777B1 (pl) |
| JP (4) | JP6045495B2 (pl) |
| KR (7) | KR102354097B1 (pl) |
| CN (5) | CN103221045A (pl) |
| AR (4) | AR083017A1 (pl) |
| AU (4) | AU2011301901B2 (pl) |
| BR (4) | BR112013006352A2 (pl) |
| CA (8) | CA2811559A1 (pl) |
| CL (4) | CL2013000734A1 (pl) |
| CY (3) | CY1121024T1 (pl) |
| DK (9) | DK2616068T3 (pl) |
| ES (10) | ES2904479T3 (pl) |
| HU (5) | HUE039090T2 (pl) |
| IL (4) | IL225281A0 (pl) |
| MX (4) | MX2013003002A (pl) |
| MY (4) | MY168763A (pl) |
| NZ (1) | NZ608751A (pl) |
| PL (7) | PL3050563T3 (pl) |
| PT (7) | PT2616069T (pl) |
| RU (4) | RU2013116405A (pl) |
| SG (4) | SG188573A1 (pl) |
| SI (5) | SI3050563T1 (pl) |
| TR (1) | TR201909249T4 (pl) |
| TW (4) | TW201240661A (pl) |
| UA (1) | UA112973C2 (pl) |
| WO (4) | WO2012037484A1 (pl) |
| ZA (4) | ZA201302194B (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3241553B1 (en) * | 2009-02-13 | 2019-04-10 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| CA2785822C (en) | 2010-01-11 | 2019-06-25 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
| US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
| AU2012287243A1 (en) * | 2011-07-22 | 2014-02-20 | Allergan, Inc. | Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye |
| US9095576B2 (en) | 2011-11-21 | 2015-08-04 | Allergan, Inc. | Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases |
| USD794650S1 (en) | 2014-11-28 | 2017-08-15 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with a graphical user interface |
| CN108310442B (zh) * | 2017-01-17 | 2021-08-27 | 台北科技大学 | 眼科用组合物 |
| KR102050506B1 (ko) | 2017-06-20 | 2019-11-29 | 한국식품연구원 | 망막 질환 예방, 개선, 완화 또는 치료용 조성물 |
| CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
| CN112552314B (zh) * | 2018-08-24 | 2022-03-04 | 杭州阿诺生物医药科技有限公司 | Sting激动剂小分子抗肿瘤化合物及其应用 |
| AU2022258105A1 (en) * | 2021-04-16 | 2023-10-26 | Ads Therapeutics Llc | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs |
| IL322606A (en) * | 2023-02-08 | 2025-10-01 | Bausch & Lomb Ireland Ltd | Alpha-2-adrenergic agonists for improving vision |
| WO2025179071A1 (en) * | 2024-02-20 | 2025-08-28 | Bausch + Lomb Ireland Limited | Sustained-release drug delivery compositions for treating ocular diseases |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG45449A1 (en) | 1992-05-13 | 1998-01-16 | Sandoz Ltd | Ophthalmic compositions |
| US5459133A (en) * | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| AU693142B2 (en) | 1993-11-15 | 1998-06-25 | Schering Corporation | Phenyl-alkyl imidazoles as H3-receptor antagonists |
| US5474979A (en) | 1994-05-17 | 1995-12-12 | Allergan, Inc. | Nonirritating emulsions for sensitive tissue |
| EP0957073A1 (en) * | 1998-05-12 | 1999-11-17 | Schwarz Pharma Ag | Novel derivatives of 3,3-diphenylpropylamines |
| US20040214829A1 (en) * | 2000-07-14 | 2004-10-28 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| DE602004015600D1 (de) * | 2003-05-27 | 2008-09-18 | Sod Conseils Rech Applic | Neue imidazolderivative, deren herstellung und deren verwendung als medikament |
| US20060209374A1 (en) * | 2003-07-14 | 2006-09-21 | Koninklijke Philips Electronics N.V. | Projection device |
| JP5165242B2 (ja) | 2003-09-12 | 2013-03-21 | アラーガン、インコーポレイテッド | 疼痛およびα２アドレナリン受容体が関与する他の状態の処置のための方法および組成物 |
| US20050059583A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods of providing therapeutic effects using cyclosporin components |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| SI1761266T1 (sl) * | 2004-05-25 | 2013-08-30 | Galderma Pharma S.A. | Spojine, formulacije in postopki za zdravljenje ali preprečevanje vnetnih kožnih motenj |
| US20050277584A1 (en) | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
| KR20070054213A (ko) | 2004-09-24 | 2007-05-28 | 알러간, 인코포레이티드 | 특이적인 알파2 아드레날린성 아고니스트로서 작용하는4-(페닐메틸 및 치환된 페닐메틸)-이미다졸-2-티온 |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
| US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
| US20070082070A1 (en) * | 2005-10-11 | 2007-04-12 | Stookey Evangeline L | Treating skin disorders |
| US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| EP2393800B1 (en) | 2009-02-06 | 2014-10-08 | Allergan, Inc. | Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors |
| EP3241553B1 (en) * | 2009-02-13 | 2019-04-10 | Allergan, Inc. | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| US8653123B2 (en) * | 2010-09-16 | 2014-02-18 | Allergan, Inc. | Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases |
-
2011
- 2011-09-15 US US13/233,382 patent/US8653123B2/en active Active
- 2011-09-15 US US13/233,844 patent/US8501796B2/en active Active
- 2011-09-15 US US13/233,891 patent/US8492557B2/en active Active
- 2011-09-15 US US13/233,665 patent/US8492422B2/en active Active
- 2011-09-16 CN CN2011800545690A patent/CN103221045A/zh active Pending
- 2011-09-16 ES ES19194325T patent/ES2904479T3/es active Active
- 2011-09-16 KR KR1020207021626A patent/KR102354097B1/ko active Active
- 2011-09-16 DK DK11760962.8T patent/DK2616068T3/en active
- 2011-09-16 DK DK16161923T patent/DK3050564T3/da active
- 2011-09-16 CA CA2811559A patent/CA2811559A1/en active Pending
- 2011-09-16 BR BR112013006352A patent/BR112013006352A2/pt not_active IP Right Cessation
- 2011-09-16 PT PT117609636T patent/PT2616069T/pt unknown
- 2011-09-16 EP EP18157147.2A patent/EP3338777B1/en active Active
- 2011-09-16 EP EP11760963.6A patent/EP2616069B1/en active Active
- 2011-09-16 HU HUE16161922A patent/HUE039090T2/hu unknown
- 2011-09-16 ES ES16161921T patent/ES2737230T3/es active Active
- 2011-09-16 SG SG2013019591A patent/SG188573A1/en unknown
- 2011-09-16 BR BR112013006355A patent/BR112013006355A2/pt not_active IP Right Cessation
- 2011-09-16 MX MX2013003002A patent/MX2013003002A/es active IP Right Grant
- 2011-09-16 SI SI201131547T patent/SI3050563T1/sl unknown
- 2011-09-16 RU RU2013116405/15A patent/RU2013116405A/ru unknown
- 2011-09-16 AR ARP110103389A patent/AR083017A1/es not_active Application Discontinuation
- 2011-09-16 SI SI201131868T patent/SI3338777T1/sl unknown
- 2011-09-16 PT PT117609628T patent/PT2616068T/pt unknown
- 2011-09-16 PL PL16161920T patent/PL3050563T3/pl unknown
- 2011-09-16 WO PCT/US2011/051979 patent/WO2012037484A1/en not_active Ceased
- 2011-09-16 ES ES18157147T patent/ES2788051T3/es active Active
- 2011-09-16 DK DK18160174.1T patent/DK3348264T3/da active
- 2011-09-16 DK DK19194325.7T patent/DK3636263T3/da active
- 2011-09-16 HU HUE16161923A patent/HUE047476T2/hu unknown
- 2011-09-16 PL PL16161923T patent/PL3050564T3/pl unknown
- 2011-09-16 TW TW100133488A patent/TW201240661A/zh unknown
- 2011-09-16 PT PT181571472T patent/PT3338777T/pt unknown
- 2011-09-16 EP EP16161920.0A patent/EP3050563B1/en active Active
- 2011-09-16 WO PCT/US2011/051926 patent/WO2012037453A1/en not_active Ceased
- 2011-09-16 PL PL16161922T patent/PL3053576T3/pl unknown
- 2011-09-16 PL PL18160174T patent/PL3348264T3/pl unknown
- 2011-09-16 ES ES11760963.6T patent/ES2613509T3/es active Active
- 2011-09-16 NZ NZ60875111A patent/NZ608751A/en unknown
- 2011-09-16 KR KR1020137009502A patent/KR101840500B1/ko active Active
- 2011-09-16 SI SI201131819T patent/SI3050564T1/sl unknown
- 2011-09-16 SI SI201131550T patent/SI3053576T1/sl unknown
- 2011-09-16 EP EP19194325.7A patent/EP3636263B1/en active Active
- 2011-09-16 KR KR1020137009505A patent/KR20140005154A/ko not_active Withdrawn
- 2011-09-16 MX MX2013003004A patent/MX2013003004A/es active IP Right Grant
- 2011-09-16 BR BR112013006362A patent/BR112013006362A2/pt not_active IP Right Cessation
- 2011-09-16 HU HUE18157147A patent/HUE048725T2/hu unknown
- 2011-09-16 DK DK11760963.6T patent/DK2616069T3/en active
- 2011-09-16 DK DK16161922.6T patent/DK3053576T3/en active
- 2011-09-16 RU RU2013116763/15A patent/RU2013116763A/ru not_active Application Discontinuation
- 2011-09-16 ES ES11760958.6T patent/ES2593612T3/es active Active
- 2011-09-16 ES ES16161920.0T patent/ES2687420T3/es active Active
- 2011-09-16 TW TW100133491A patent/TWI591058B/zh active
- 2011-09-16 EP EP16161923.4A patent/EP3050564B1/en active Active
- 2011-09-16 PL PL18157147T patent/PL3338777T3/pl unknown
- 2011-09-16 HU HUE16161920A patent/HUE038698T2/hu unknown
- 2011-09-16 AU AU2011301901A patent/AU2011301901B2/en active Active
- 2011-09-16 DK DK18157147.2T patent/DK3338777T3/da active
- 2011-09-16 PT PT16161920T patent/PT3050563T/pt unknown
- 2011-09-16 AR ARP110103390A patent/AR083018A1/es unknown
- 2011-09-16 ES ES16161923T patent/ES2760920T3/es active Active
- 2011-09-16 AR ARP110103391A patent/AR083019A1/es unknown
- 2011-09-16 CA CA2812195A patent/CA2812195A1/en not_active Abandoned
- 2011-09-16 MY MYPI2013000931A patent/MY168763A/en unknown
- 2011-09-16 JP JP2013529372A patent/JP6045495B2/ja active Active
- 2011-09-16 WO PCT/US2011/052004 patent/WO2012037499A1/en not_active Ceased
- 2011-09-16 ES ES11760962.8T patent/ES2607084T3/es active Active
- 2011-09-16 SG SG2013019567A patent/SG188571A1/en unknown
- 2011-09-16 RU RU2013116541A patent/RU2612351C2/ru active
- 2011-09-16 RU RU2013116403/15A patent/RU2013116403A/ru not_active Application Discontinuation
- 2011-09-16 PL PL11760963T patent/PL2616069T3/pl unknown
- 2011-09-16 CA CA3122745A patent/CA3122745A1/en active Pending
- 2011-09-16 MY MYPI2013000932A patent/MY161607A/en unknown
- 2011-09-16 EP EP11760958.6A patent/EP2616066B1/en active Active
- 2011-09-16 KR KR1020137009503A patent/KR101840501B1/ko active Active
- 2011-09-16 EP EP19217499.3A patent/EP3698789A1/en not_active Withdrawn
- 2011-09-16 CA CA3116249A patent/CA3116249A1/en active Pending
- 2011-09-16 HU HUE18160174A patent/HUE049573T2/hu unknown
- 2011-09-16 CA CA3079450A patent/CA3079450A1/en active Pending
- 2011-09-16 EP EP11760961.0A patent/EP2616067B1/en active Active
- 2011-09-16 CN CN2011800546049A patent/CN103209694A/zh active Pending
- 2011-09-16 AU AU2011301847A patent/AU2011301847B2/en active Active
- 2011-09-16 CN CN201510767798.7A patent/CN105412092B/zh active Active
- 2011-09-16 DK DK16161920.0T patent/DK3050563T3/en active
- 2011-09-16 EP EP16161922.6A patent/EP3053576B1/en active Active
- 2011-09-16 MX MX2013003008A patent/MX2013003008A/es active IP Right Grant
- 2011-09-16 ES ES16161922.6T patent/ES2684055T3/es active Active
- 2011-09-16 BR BR112013006320-3A patent/BR112013006320B1/pt active IP Right Grant
- 2011-09-16 MX MX2013003009A patent/MX2013003009A/es active IP Right Grant
- 2011-09-16 TW TW100133498A patent/TW201240662A/zh unknown
- 2011-09-16 KR KR1020137009506A patent/KR101952457B1/ko active Active
- 2011-09-16 SG SG2013019575A patent/SG188572A1/en unknown
- 2011-09-16 AU AU2011301856A patent/AU2011301856C1/en active Active
- 2011-09-16 WO PCT/US2011/051990 patent/WO2012037490A1/en not_active Ceased
- 2011-09-16 SG SG2013019559A patent/SG188570A1/en unknown
- 2011-09-16 TW TW100133487A patent/TW201305116A/zh unknown
- 2011-09-16 TR TR2019/09249T patent/TR201909249T4/tr unknown
- 2011-09-16 CA CA3077732A patent/CA3077732A1/en active Pending
- 2011-09-16 KR KR1020207011231A patent/KR102139905B1/ko active Active
- 2011-09-16 DK DK16161921.8T patent/DK3078376T3/da active
- 2011-09-16 EP EP11760962.8A patent/EP2616068B1/en active Active
- 2011-09-16 EP EP18160174.1A patent/EP3348264B1/en active Active
- 2011-09-16 JP JP2013529373A patent/JP6073229B2/ja active Active
- 2011-09-16 AR ARP110103392A patent/AR083020A1/es unknown
- 2011-09-16 JP JP2013529360A patent/JP2013541527A/ja not_active Withdrawn
- 2011-09-16 PT PT161619234T patent/PT3050564T/pt unknown
- 2011-09-16 UA UAA201304644A patent/UA112973C2/uk unknown
- 2011-09-16 CN CN201180053895XA patent/CN103200942A/zh active Pending
- 2011-09-16 CN CN201180053886.0A patent/CN103200941B/zh active Active
- 2011-09-16 AU AU2011301932A patent/AU2011301932C1/en active Active
- 2011-09-16 KR KR1020197004880A patent/KR102104760B1/ko active Active
- 2011-09-16 ES ES18160174T patent/ES2781681T3/es active Active
- 2011-09-16 EP EP16161921.8A patent/EP3078376B1/en active Active
- 2011-09-16 EP EP20153104.3A patent/EP3659600A1/en not_active Withdrawn
- 2011-09-16 PT PT181601741T patent/PT3348264T/pt unknown
- 2011-09-16 MY MYPI2013000930A patent/MY191369A/en unknown
- 2011-09-16 CA CA2812191A patent/CA2812191C/en active Active
- 2011-09-16 MY MYPI2013000907A patent/MY173846A/en unknown
- 2011-09-16 JP JP2013529371A patent/JP2013537236A/ja not_active Withdrawn
- 2011-09-16 CA CA2812197A patent/CA2812197C/en active Active
- 2011-09-16 PT PT16161922T patent/PT3053576T/pt unknown
- 2011-09-16 PL PL11760962.8T patent/PL2616068T3/pl unknown
- 2011-09-16 SI SI201131857T patent/SI3348264T1/sl unknown
-
2013
- 2013-03-17 IL IL225281A patent/IL225281A0/en unknown
- 2013-03-17 IL IL225280A patent/IL225280A0/en active IP Right Grant
- 2013-03-17 IL IL225278A patent/IL225278A/en active IP Right Grant
- 2013-03-17 IL IL225282A patent/IL225282A0/en unknown
- 2013-03-18 CL CL2013000734A patent/CL2013000734A1/es unknown
- 2013-03-18 CL CL2013000735A patent/CL2013000735A1/es unknown
- 2013-03-18 CL CL2013000733A patent/CL2013000733A1/es unknown
- 2013-03-18 CL CL2013000736A patent/CL2013000736A1/es unknown
- 2013-03-25 ZA ZA2013/02194A patent/ZA201302194B/en unknown
- 2013-03-25 ZA ZA2013/02193A patent/ZA201302193B/en unknown
- 2013-03-27 ZA ZA2013/02291A patent/ZA201302291B/en unknown
- 2013-03-27 ZA ZA2013/02288A patent/ZA201302288B/en unknown
- 2013-06-13 US US13/916,888 patent/US20130289088A1/en not_active Abandoned
- 2013-06-24 US US13/925,502 patent/US20130296394A1/en not_active Abandoned
- 2013-11-04 US US14/071,090 patent/US8853251B2/en active Active
-
2015
- 2015-01-29 US US14/608,458 patent/US20150148394A1/en not_active Abandoned
-
2016
- 2016-08-18 US US15/240,219 patent/US20160354346A1/en not_active Abandoned
-
2018
- 2018-08-13 CY CY181100852T patent/CY1121024T1/el unknown
-
2020
- 2020-03-20 CY CY20201100265T patent/CY1122958T1/el unknown
- 2020-04-21 CY CY20201100365T patent/CY1122809T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201302291B (en) | Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol for lowering intraocular pressure | |
| ZA201005510B (en) | Production of ethanol from methanol | |
| IL210149A0 (en) | Isolation of cyclopamine | |
| DK3566703T3 (da) | Farmaceutiske sammensætninger omfattende (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| IL226384A0 (en) | Pharmaceutical preparations containing (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol | |
| EP2549014A4 (de) | Verfahren zur einstellung der biegung von beschichtetem papier | |
| HK1163558A (en) | Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl) methanol | |
| HK1157673A (en) | Isolation of cyclopamine | |
| HK1167598A (en) | Method for improving bioavailability of latanoprost | |
| AU2008901308A0 (en) | System for making component parts of a structure | |
| AU2008902085A0 (en) | A Continuous System for Production of Hydrogen | |
| AU2008905224A0 (en) | A Continuous System for Production of Hydrogen |